Inactief instrument

Andere talen Endonovo Therapeutics, Inc. Other OTC

Aandelen

ENDV

US29272H3003

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc	28/03
Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions	04/03
Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/12
Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million	04/12
Endonovo's SofPulse® Secures Taiwan FDA Approval	12-10-23
Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval	12-10-23
Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution	22-08-23
Endonovo Therapeutics, Inc.'s SofPulse Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution	22-08-23
Endonovo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21-08-23
Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update	08-08-23
New to The Street TV Signs 6 Part Series, Featuring Endonovo Therapeutics, Inc.	22-06-23
Endonovo Pending Agreement to Develop Telehealth Division	07-06-23
Endonovo Therapeutics, Inc. Announces Pending Agreement to Develop Telehealth Division	07-06-23
Endonovo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	22-05-23
Endonovo Launches SofPulse® into the Veterans Administration	02-05-23
Endonovo Therapeutics, Inc. Launches SofPulse into the Veterans Administration	02-05-23
Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies	25-04-23
Endonovo Therapeutics, Inc. Announces Moving Forward in Its Clinical Development in the Field of Traumatic Brain Injury Treatment	25-04-23
ENDONOVO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	17-04-23
Endonovo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17-04-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Endonovo Therapeutics, Inc. Other OTC

Aandelen

ENDV

US29272H3003

Andere talen

Filters